2. Anti-infection
  3. Bacterial Antibiotic
  4. Faropenem daloxate

Faropenem daloxate  (Synonyms: Faropenem medoxil)

Cat. No.: HY-10004 Purity: 98.18%
SDS
COA
Handling Instructions Technical Support

Faropenem daloxate (Faropenem medoxil) is an orally active beta-lactam antibiotic. Faropenem daloxate has excellent in vitro activity against Streptococcus pneumonia, Haemophilus influenza, and other key pathogens implicated in acute bacterial rhino sinusitis. Faropenem daloxate can be studied in research for respiratory pathogens and acute bacterial sinusitis.

For research use only. We do not sell to patients.

Faropenem daloxate Chemical Structure

Faropenem daloxate Chemical Structure

CAS No. : 141702-36-5

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Faropenem daloxate:

Faropenem daloxate Related Antibodies

Top Publications Citing Use of Products

View All Antibiotic Isoform Specific Products:

View All Isoforms
Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Faropenem daloxate (Faropenem medoxil) is an orally active beta-lactam antibiotic. Faropenem daloxate has excellent in vitro activity against Streptococcus pneumonia, Haemophilus influenza, and other key pathogens implicated in acute bacterial rhino sinusitis. Faropenem daloxate can be studied in research for respiratory pathogens and acute bacterial sinusitis[1][2][3][4][5].

IC50 & Target

β-lactam

 

Parmacokinetics
Species Dose Route Indicator value
Dog 100 mg/kg p.o. Tmax 1.5 hr
Dog 1400 mg/kg p.o. AUC0-t 551 μg·h/mL
Dog 1400 mg/kg p.o. Cmax 130 μg/mL
Dog 300 mg/kg p.o. Tmax 1.5 hr
Dog 600 mg/kg p.o. Tmax 1.5 hr
Dog 100 mg/kg p.o. AUC0-t 171 μg·h/mL
Dog 100 mg/kg p.o. Cmax 49.1 μg/mL
Dog 1400 mg/kg p.o. Tmax 3 hr
Dog 300 mg/kg p.o. AUC0-t 388 μg·h/mL
Dog 300 mg/kg p.o. Cmax 101 μg/mL
Dog 600 mg/kg p.o. AUC0-t 507 μg·h/mL
Dog 600 mg/kg p.o. Cmax 123 μg/mL
In Vivo

Faropenem daloxate (Compound FPM) (0-144 mg/kg/day, p.o., 28 consecutive days) reduces the absolute erythrocyte count and hemoglobin in juvenile beagle dog[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Molecular Weight

397.40

Formula

C17H19NO8S
CAS No.
Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C(N1[C@@]2(SC([C@@H]3OCCC3)=C1C(OCC4=C(OC(O4)=O)C)=O)[H])[C@]2([H])[C@H](O)C
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : ≥ 100 mg/mL (251.64 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : < 0.1 mg/mL (insoluble)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.5164 mL 12.5818 mL 25.1636 mL
5 mM 0.5033 mL 2.5164 mL 5.0327 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (6.29 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (6.29 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.5164 mL 12.5818 mL 25.1636 mL 62.9089 mL
5 mM 0.5033 mL 2.5164 mL 5.0327 mL 12.5818 mL
10 mM 0.2516 mL 1.2582 mL 2.5164 mL 6.2909 mL
15 mM 0.1678 mL 0.8388 mL 1.6776 mL 4.1939 mL
20 mM 0.1258 mL 0.6291 mL 1.2582 mL 3.1454 mL
25 mM 0.1007 mL 0.5033 mL 1.0065 mL 2.5164 mL
30 mM 0.0839 mL 0.4194 mL 0.8388 mL 2.0970 mL
40 mM 0.0629 mL 0.3145 mL 0.6291 mL 1.5727 mL
50 mM 0.0503 mL 0.2516 mL 0.5033 mL 1.2582 mL
60 mM 0.0419 mL 0.2097 mL 0.4194 mL 1.0485 mL
80 mM 0.0315 mL 0.1573 mL 0.3145 mL 0.7864 mL
100 mM 0.0252 mL 0.1258 mL 0.2516 mL 0.6291 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Faropenem daloxate Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Faropenem daloxate141702-36-5Faropenem medoxilBacterialAntibioticbeta-lactam antibioticStreptococcus pneumoniaHaemophilus influenzaacute bacterial sinusitisInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Faropenem daloxate
Cat. No.:
HY-10004
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Portuguese - PT (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.